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ABSTRACT
This study examined patterns of medicalization in substance use disorder (SUD) that are aligned
with the goals of the Affordable Care Act (ACA). Using a nationally representative sample of SUD
treatment programs, we examined changes in several treatment domains. While observed
changes were modest, they were in directions that support the thrust of the ACA. Specifically,
we found an increase in the percentage of treatment referrals from other health care providers.
We found an increase in the number of physicians for programs that did have a physician on staff,
and an increase in counselors certified in treating alcohol and drug addiction. There was sig-
nificant growth in the availability of oral and injectable naltrexone but not of other pharma-
cotherapies. There was a decrease in support for the 12-step model and an increase on the
emphasis of a medicalized treatment model. Finally, we found a shift away from federal block
grants and other public funding, consistent with the expectations of the ACA. These data indicate
that, while progress is slow, the environment of the recent past has been supportive of the goal of
SUD treatment’s integration into mainstream medical care.
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Provisions of the Patient Protection and Affordable
Care Act (ACA) in the United States, including its
incorporation of the pre-existing mandate for parity
in insurance reimbursements for behavior disorders,
were designed to increase the number of individuals
with substance use disorders (SUDs) that have coverage
for services, thus increasing entry into SUD treatment.
In March 2016, then-President Obama reported that 20
million people who were previously uninsured had
signed up for insurance, including those who signed
up through either state-based exchanges or state
Medicaid expansion, and young adults who were able
to stay on their parents’ insurance until age 26 (Henry
J. Kaiser Foundation 2016). A significant number of
these new enrollees are likely to have an SUD (Buck
2011; Garfield et al. 2011), with one projection indicat-
ing around 3.6 million newly insured individuals with
SUD treatment needs (Mark et al. 2015).
In addition to parity in coverage, the ACA aims to
integrate SUD services into primary care to rectify
long-standing problems with system fragmentation
(Barry and Huskamp 2011; Roman, Abraham, and
Knudsen 2011; Samet, Friedmann, and Saitz 2001). At
the same time, integration can be achieved through
adding access to primary care services to SUD treat-
ment (Weisner et al. 2001). This study draws upon data
from a national study of U.S. SUD treatment programs
to examine five research questions related to the med-
icalization of treatment services that are aligned with
the goals of the ACA. First, is there evidence of an
increase in referrals into SUD treatment from primary
care physicians and other health care professionals?
Second, is there an increase in the employment of
medical professionals, including physicians, nurses
with prescribing privileges, and physician assistants in
programs? Third, is there evidence of an increase in
adoption and implementation of medication-assisted
treatment (MAT) in SUD treatment? Fourth, is there
a shift in treatment philosophy toward a medical model
of addiction, and a change in the availability of health-
related services in SUD treatment providers? Finally, is
there an increase in revenues from Medicaid, Medicare,
and private insurance, and a decrease in funding from
federal block grants and other public grants? These
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questions tap how the ACA may be impacting SUD
treatment through framing multiple aspects of treat-
ment within medicalized practices.
There are several mechanisms that are likely to
increase physicians’ awareness of their patients’ SUD
treatment needs as well as options to treat them. These
include the creation of “medical homes” for people with
co-occurring disorders and SUDs (Barry and Huskamp
2011; Urada et al. 2014), and the evidence-based prac-
tice of Screening, Brief Intervention, and Referral to
Treatment (SBIRT) (Babor et al. 2007; Madras et al.
2009; WHO 2008), designed for medical personnel for
both early detection and interventions for individuals
with risky alcohol and drug use (SAMHSA 2011).
Although most primary care physicians ask patients
about their alcohol use, fewer use recommended
screening protocols (Friedmann et al. 2000). Further,
studies on the willingness of primary care physicians to
add treatment of opioid addiction with buprenorphine
to their practices have revealed resistance to such adop-
tion as well as considerable geographic disparity in
adoption patterns (Hutchinson et al. 2014; Knudsen
2015). Nevertheless, we examine the extent to which
programs are receiving referrals from health care pro-
viders as an indicator of this dimension of the ACA’s
emphases.
A related dimension of the ACA’s emphasis on
integration is new or increased employment of med-
ical staff in SUD treatment programs through its
reimbursement procedures and prescription drug
coverage (Buck 2011). Both the use of pharma-
cotherapies and Medicaid-reimbursable clinic services
typically require delivery under the direction of a
physician and medical professionals with appropriate
licensure (Buck 2011). There are also expected
changes in required training for the counseling work-
force, due to reimbursement plans requiring practi-
tioners with advanced degrees and licensing. This is a
particular challenge, with about 50% of counselors
employed in addiction treatment lacking graduate
degrees (Aletraris et al. 2016; Aletraris, Shelton, and
Roman 2015; Bride et al. 2016).
With the expected growth in staffing of medical
professionals, opportunities for adoption of MAT
should also increase (Edmond et al. 2015; Knudsen,
Roman, and Oser 2010; Thomas et al. 2003). Previous
studies have looked at the adoption of individual
pharmacotherapies (Aletraris, Edmond, and Roman
2015; Knudsen and Roman 2016), whereas the present
study considers the breadth of pharmacotherapy ser-
vices, including the adoption of psychotropic and SUD
medications as well as implementation of SUD
medications.
Associated with medicalization of treatment is a
trend toward embracing a medical model of addiction,
as opposed to endorsing other treatment models, parti-
cularly an emphasis on the 12-step program. Similarly,
integration goals of the ACA encourage increased pro-
vision of on-site health-related services, such as HIV
testing, which are important for substance-abusing
populations.
Finally, SUD treatment programs have historically
relied on block grants and state contracts (Mark et al.
2011; McCarty et al. 2009), but some treatment pre-
viously covered by block grants may instead be covered
by the expansion of Medicaid under the ACA (Buck
2011; Woodward 2015). Medicaid and private insur-
ance plans will become primary payers for most SUD
treatment services. Thus, in response to the ACA, SUD
programs would be expected to have increased utiliza-
tion of all types of third-party payments for services.
This study included two data collections that exam-
ine the characteristics of organizations in the early
stages of implementation of the ACA. Some of the
changes intended by the ACA may be transformational
at the organizational level for many SUD programs.
Such change does not occur rapidly. Following ACA
enactment, large numbers of enrollees in health plans
were not seen until more than three years after the
legislation was passed (Henry J. Kaiser Foundation
2014). Furthermore, at this writing, intentions to repeal
and replace provisions of the ACA are widespread but
ambiguous, with complete disappearance of all ACA
provisions unlikely. The ACA is a “machine in motion”
and includes interlocking provisions, adding uncer-
tainty as to how the long-term future of SUD treatment
will be affected.
Methods
Sample
Data were collected from a national sample of SUD
treatment organizations during two 24-month rounds
of face-to-face interviews. The first round of data col-
lection ended in January 2012, while the second ended
in January 2014. Treatment programs in the 48 con-
tinental states and the District of Columbia were ran-
domly sampled from the SAMHSA’s Substance Abuse
Treatment Facility Locator.
To be eligible, programs were required to be open to
the general public, thus excluding Veterans Health
Administration facilities, correctional facilities, and
court-ordered DUI classes. They were also required to
employ at least two full-time equivalent (FTE) employ-
ees, and offer a minimum level of care at least
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equivalent to Level I outpatient services, as defined by
the ASAM placement criteria (Mee-Lee et al. 1996).
Detoxification-only programs and methadone-only
programs were excluded from the study. Programs
were required to have at least 25% of their patients
admitted with alcohol as a primary substance abuse
problem. Centers screened as ineligible during a tele-
phone screening were replaced by a random selection
from the SAMHSA database. The research procedures
were approved by the Institutional Review Board of the
University of Georgia.
Data were collected using face-to-face interviews
with the administrator and/or clinical director of each
treatment program. A team of trained interviewers with
at least a bachelor’s level of education conducted all
interviews. In the first wave of data collection, 307
programs participated. There were 200 programs from
this sample that participated in the second wave
(response rate 65%), which took place approximately
24 months after the initial interview. These 200 centers
are used in our analyses.
Measures
Differences in patterns of medicalization between the two
time periods were assessed across several domains. First,
administrators were asked for the percentage of clients
referred from primary care physicians and from other
health providers (e.g., ERs and general hospitals). Second,
administrators responded to a series of staffing questions.
They were asked how many counselors were employed in
the program and how many held at least a master’s-level
degree. This was converted to a percentage. To establish the
scope of staff with specific medical training, administrators
were also asked for the number of FTE psychiatrists, non-
psychiatric physicians, nurses, physician assistants with
prescribing privileges, and other medical staff without pre-
scribing privileges on payroll. Using the number of total
FTE employees, which includes the categories described
earlier, administrators and other staff, a percentage was
created for each category.
Third, respondents were asked a series of questions
regarding specific medications for SUD and co-occurring
psychiatric disorders. The variables for each medication
were coded “1” if the treatment program reported current
use of the medication, and “0” if it did not. We created
dichotomous variables for the following psychiatric medi-
cations: SSRIs (e.g., Prozac, Zoloft, Paxil), other anti-
depressants (monoamine oxidase inhibitors, tricyclic anti-
depressants), other anti-anxiety medications (e.g. Xanax,
Valium), and antipsychotic medications (e.g., lithium, clo-
zapine, risperidone). We also created dichotomous vari-
ables for the following SUD medications: acamprosate,
buprenorphine, disulfiram, oral naltrexone, and injectable
naltrexone. For SUD medications, we created continuous
variables measuring the percentage of a center’s patients
that were prescribed each medication.
Fourth, questions were asked regarding the pro-
gram’s treatment philosophy as well as the provision
of health-related services. Directors were asked the
extent to which the organization’s therapeutic style
emphasized the 12-step model and the medical model
of addictions, respectively, using a Likert scale
(“0” = no extent; “5” = a very great extent). Provision
of on-site, non-SUD health-related services was mea-
sured using dichotomous variables for each of the fol-
lowing: primary care, HIV testing, Hepatitis C testing,
and treatment of co-occurring psychiatric disorders.
Finally, administrators were asked for the percentage
of revenues from the following sources: Medicaid,
Medicare, private insurance, client fees, criminal jus-
tice, federal block grants, and other public grants
(including state and local public funding).
McNemar’s chi-square tests were used to compare
baseline and follow-up results on dichotomous mea-
sures. Paired t-tests were used to compare continuous
measures that were normally distributed, and
Wilcoxon’s signed-rank tests were used to compare
continuous variables that were skewed. Reported
mean percentages refer to all treatment programs,
including those that did not employ that category
(e.g., the mean percentage of referrals from primary
care physicians included programs with no referrals
from primary care).
Results
We found that 64.5% of programs received referrals
from primary care physicians in the first round of
data collection, and 69% reported receiving referrals
from primary care physicians in the second wave
(Table 1). While this increase was not significant,
the small increase in the mean percentage of referrals
within a program that came from primary care phy-
sicians was significant (Z = 3.58, p < .001). There was
a larger increase in the number of programs that
reported receiving referrals from health care provi-
ders other than primary care physicians. In the first
wave, 68.5% of programs received referrals from
other health care providers, whereas 79% received
them in the second wave (McNemar’s χ2 = 21.35,
p < .001). On average, 7.4% of a treatment program’s
referrals came from such health care providers in the
first wave, compared to 13.3% in the second wave
(Z = 7.17, p < .001). Overall, 79% of programs
received referrals from either primary care or other
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health care providers in the first wave, compared to
87% in the second wave (McNemar’s χ2 = 9.00,
p < .01, not shown).
Less than a quarter of programs had a psychiatrist
on staff at either wave. The number of FTE psychia-
trists ranged from 0–10 in wave one, and 0–12 in
wave two. In terms of percentages, this represented
0–33.3% of all FTE employees on staff in the first
wave, and 0–76.9% of all FTE employees in the
second wave. There were no significant changes in
the availability, number, or percentage of FTE psy-
chiatrists on staff.
There was a slight increase, from 10.5% to 15.5%, in
programs with a non-psychiatrist physician on staff
(McNemar’s χ2 = 3.90, p = .07). Similarly, there was a
modest increase in the number of FTE physicians on
payroll (Z = 2.21, p < .05), and in their percentage
compared to all FTE employees in the program
(Z = 2.12, p < .05). While these percentages indicated
that, on average, less than 2% of FTE employees were
physicians, this ranged from 0% to 20%. Less than a
third of programs (27% in wave one; 29% in wave two)
had either a psychiatrist or another physician on staff.
An additional 39.5% of programs in wave one and 36%
in wave two reported having a physician available on
contract. About 62% of programs either had a physi-
cian on contract or on their payroll (not shown).
A larger percentage of programs had a nurse on staff,
with 40% indicating doing so in the first wave and 38%
employing a nurse in the second wave. The number of
FTE nurses ranged from 0–20 during both time periods.
As with psychiatrists, there were no significant changes
in the employment of nurses in the treatment centers.
Only 4% of centers in wave one and 3% in wave two had
a physician assistant on staff and, on average, physician
assistants represented .12% of FTE employees in the
center. We did find a modest increase in the employ-
ment of other medical staff without prescribing privi-
leges (McNemar’s χ2 = 4.45, p < .05).
There was a non-significant increase in the percen-
tage of counselors with an M.A. degree or higher. On
average, 43.7% of counselors had a graduate degree in
the first wave, compared to 47% in the second wave
(t = 1.56, p = .06). The majority of programs had at
least one certified alcohol and drug addiction counselor
on staff. However, there was a significant increase in
the percentage of the counseling staff that was certified
(an increase from 57% to 62%; t = 2.13, p < .05).
Overall, MAT adoption rates were modest through-
out the study (Table 2). We found that 42% of pro-
grams offered medications for SUD and/or co-
occurring disorders in the first wave, compared to
47% in the second wave. Although a majority of pro-
grams reported that they offered treatment for co-
occurring disorders (see Table 3), adoption of common
types of psychiatric medications was not extensive.
SSRIs were the most common type of psychotropic
medication offered (40.5% in the first wave; 43.5% in
the second wave), while anti-anxiety medications were
the least likely to be prescribed (16.5% in wave one;
17.5% in wave two). The only significant increase was
Table 1. Referral and staffing characteristics in treatment programs
(N = 200).
Wave 1 Wave 2
Significance
level†
Receives referrals from
primary care
physicians
64.5% (129) 69.0% (138)
% of program referrals
from primary care
4.37 (8.50) 5.54 (8.25) ***
Receives referrals from
other health care
providers
68.5% (137) 79.0% (158) **
% of program referrals
from other health care
professionals
7.39 (12.28) 13.31 (18.23) ***
Psychiatrist on staff 22.0% (44) 19.0% (38)
# of FTE psychiatrists in
program
0.25 (0.99) 0.25 (1.08)
% FTE psychiatrists in
program
0.96 (3.78) 1.44 (7.29)
Other physician on
staff
10.5% (21) 15.5% (31)
# FTE other physicians in
program
0.08 (0.33) 0.12 (0.43) *
% of FTE other
physicians in program
0.35 (1.72) 1.38 (8.29) *
Nurse on staff 40.0% (80) 38.0% (76)
# of FTE nurses in
program
1.14 (2.94) 1.20 (3.21)
% FTE nurses in program 3.36 (7.02) 3.58 (8.61)
Physician assistant
with prescribing
privileges on staff
4.0% (8) 3.0% (6)
# of physician assistants
in program
0.05 (0.25) 0.08 (0.49)
% physician assistants in
program
0.12 (0.66) 0.12 (0.70)
Other medical staff
without prescribing
privileges on staff
18.5% (37) 25.5% (51) *
# of other medical staff
in program
1.47 (5.52) 1.60 (6.36)
% of other medical staff
in program
3.22 (9.52) 3.69 (9.85)
Counselors with M.A.
degree or higher on
staff
78.0% (156) 80.5% (161)
% counselors with M.A.
degrees in program
43.72 (34.25) 46.95 (35.50)
Certified alcohol &
drug addiction
counselor on staff
83.0% (166) 87.0% (174)
% certified counselors in
program
56.95 (37.20) 61.89 (35.81) *
FTE employees in
program
21.74 (31.68) 21.30 (28.95)
†Wilcoxon’s signed rank tests, paired t-tests, or McNemar’s chi-square tests.
*p < .05, **p < .01, ***p < .001.
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in the availability of other antidepressants (i.e., MAO
inhibitors and tricyclic antidepressants) (from 36% to
41.5% of programs; McNemar’s χ2 = 4.83, p < .05).
Adoption of SUD medications was also modest, with
29.5% of programs indicating their use in the first wave
and 33% in the second wave. There were two SUD
medications with significant increases in the percentage
of programs using them. Availability of oral naltrexone
increased from 13% to 19% of programs (McNemar’s
χ2 = 8.05, p < .01). We also found a small but signifi-
cant increase in the use of injectable naltrexone for
opioid patients (but not for alcohol patients), from 2%
to 6.5% (McNemar’s χ2 = 8.33, p < .01). Similarly, there
was a small increase in the percentage of opioid
patients receiving injectable naltrexone (Z = 2.54,
p < .05). Implementation increased by an average 2%
when we only considered organizations that used any
SUD medications (not shown). There was a decrease in
the percentage of programs using disulfiram that
approximated significance (McNemar’s χ2 = 3.86,
p = .07). There was also a decrease in the extent of
use of disulfiram, measured by the percentage of a
program’s patients receiving the medication (Z = 2.63,
p < .01). Finally, while there were no changes in the
number of programs that offered acamprosate, there
was a decrease in the percentage of patients receiving
the medication (Z = 2.84, p < .01).
Data regarding programs’ treatment philosophy and
availability of on-site health-related services are pre-
sented in Table 3. There was a small but significant
decrease in the extent to which programs endorsed the
12-step model (t = 1.87, p < .05), and an increase in the
support for the medical model of SUD treatment
(t = 2.05, p < .05). Nonetheless, support for the medical
model was modest and lower than endorsement of the
12-step model. In analyses not shown, endorsement of
the medical model was greater than that of the 12-step
model among organizations that offered MAT.
Just 11% of programs reported no use of the 12-step
model at all during the baseline study, while 14.5% did
Table 2. Availability of medication-assisted treatment in treatment
programs (N = 200).
Wave 1 Wave 2
Significance
level†
Program offers
medication-assisted
treatment (includes
psychiatric and SUD
medications)
42.0% (84) 47.0% (94)
Program prescribes
SSRIs
40.5% (81) 43.5% (87)
Program prescribes
other antidepressants
36.0% (72) 41.5% (83) *
Program prescribes
other anti-anxiety
medications
16.5% (33) 17.5% (35)
Program prescribes
antipsychotic
medications
37.5% (75) 36.5% (73)
Program prescribes
medications
specifically for SUD
29.5% (59) 33.0% (66)
Program prescribes
acamprosate
20.0% (40) 17.0% (34)
% of patients in program
receiving acamprosate
4.77 (16.96) 1.08 (4.24) **
Program prescribes
buprenorphine
17.0% (34) 20.5% (41)
Program prescribes
buprenorphine for
detoxification
12.0% (24) 12.5% (25)
% of patients in program
receiving
buprenorphine for
detoxification
4.07 (17.79) 3.74 (16.45)
Program prescribes
buprenorphine for
maintenance
12.0% (24) 16.5% (33)
% of patients in program
receiving
buprenorphine for
maintenance
3.48 (15.25) 3.60 (13.22)
Program prescribes
disulfiram
14.0% (28) 9.0% (18)
% of patients in program
receiving disulfiram
1.24 (7.42) 0.19 (1.12) **
Program prescribes oral
naltrexone
13.0% (26) 19.0% (38) **
%of patients in program
receiving oral
naltrexone
3.19 (13.80) 1.27 (6.34)
Program prescribes
injectable naltrexone
for alcohol patients
6.0% (12) 9.0% (18)
% of alcohol patients in
program receiving
injectable naltrexone
0.42 (2.77) 0.69 (4.33)
Program prescribes
injectable naltrexone
for opioid patients
2.0% (4) 6.5% (13) **
% of opioid patients in
program receiving
injectable naltrexone
0.11 (1.17) 0.94 (6.81) *
†Wilcoxon’s signed-rank tests or McNemar’s chi-square tests.
*p < .05, **p < .01, ***p < .001.
Table 3. Treatment philosophy and availability of health-related
services in treatment programs (N = 200).
Wave 1 Wave 2
Significance
level†
Program treatment
philosophy
Twelve-step model
(“0” = no extent; “5” = a
very great extent)
3.24 (1.70) 3.03 (1.70) *
Medical model of addiction
(“0” = no extent; “5” = a
very great extent)
2.68 (1.74) 2.96 (1.65) *
Program provides:
Primary care 13.5% (27) 13.0% (26)
Dental care 3.5% (7) 3.5% (7)
On-site HIV testing 35.0% (70) 27.0% (54)
On-site Hepatitis C testing 14.5% (29) 10.5% (21)
Treatment for co-occurring
disorders
76.0% (152) 82.0% (164) *
†Paired t-tests or McNemar’s chi-square tests.
*p < .05, **p < .01, ***p < .001.
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not use it at all in the follow-up. About 33% of pro-
grams fully endorsed the 12-step model (i.e., gave a
rating of “5” on a scale of 0–5) in the first wave, but
this dropped to 25% in the second wave. In terms of the
medical model of addiction, 18.5% of programs did not
emphasize this model at all, while 19% fully endorsed it
during the first wave. In the second wave, 12.5% of
programs did not use the medical model at all, and
20.5% reported that they emphasized the model to a
very large extent.
With the exception of treatment for co-occurring
disorders, there was limited availability of health-
related services, and no significant changes between
the two time periods. About 13% of programs provided
on-site primary care and similar percentages were
reported for Hepatitis C testing. About a third of pro-
grams offered on-site HIV testing. About three quarters
(76%) of programs provided treatment for patients’ co-
occurring disorders during the first wave. There was a
modest and significant increase to 82% approximately
24 months later (McNemar’s χ2 = 6.12, p < .05).
Table 4 presents data on sources of program reven-
ues. There were three changes between the two waves.
There was an increase in the percentage of revenues
from client fees (Z = 2.11, p < .05), and a decrease in
revenues from federal block grants (Z = 2.06, p < .05)
and other public grants (Z = 2.28, p < .05). For exam-
ple, on average, 14.5% of program revenues came from
federal block grants in the first wave, while, on average,
programs received around 11.5% of their revenues from
block grants at follow-up. There were non-significant
increases in the percentage of revenues from Medicaid,
Medicare, and private insurance.
Discussion
The ACA offers strong support for medicalization of
SUD treatment. This study examined shifts in organi-
zational activities indicative of the patterns of medica-
lized treatment that are aligned with the goals of the
ACA. The changes examined included referrals into
treatment from health care providers, employment of
medical staff, availability of MAT and other health-
related services, a treatment philosophy that empha-
sizes the medical model, and changes in revenues
from Medicaid, private insurers, and block grants.
While the interviews in the second round of data
collection occurred after the passage of the ACA,
implementation of many of its significant reforms are
complex, require substantial organizational change, and
thus are moving relatively slowly. Our findings indicate
that, while changes were modest, nearly all changes
were in directions that support the thrust of the ACA.
The ACA emphasizes greater integration of SUD treat-
ment with general and specialty medical care settings
(Tai and Volkow 2013). While there was not a signifi-
cant increase in the percentage of programs that
reported receiving any referrals from primary care pro-
viders, we did find an increase in the percentage of
their total referrals from primary care. We also found
an increase in programs that received referrals from
other health care providers, as well as an increase in
the percentage of those referrals. Yet, the percentage of
referrals was low, even in the follow-up study, with a
mean of 13% of a center’s referrals coming from health
care providers other than a primary care physician.
Both the adoption and appropriate implementation of
processes such as SBIRT in non-SUD medical practice
are challenging because of the time constraints and
competing demands faced by many practitioners
(Rahm et al. 2015).
Past studies on SUD treatment staff focused on the
training and background experience of the counseling
workforce. Less attention has been given to the pre-
sence of medical professionals and paraprofessionals
in treatment programs. We found that 38% of pro-
grams had no consistent access to a physician, either
on contract or on staff. Results also showed an
increase in the number of FTE physicians for those
programs that did have a physician on staff, an
increase in the availability of other medical staff with-
out prescribing privileges, and an increase in the per-
centage of counselors certified in alcohol and drug
addiction. These trends show an important change
underway, given the stipulations on reimbursement
of treatment services delivered by qualified profes-
sionals. Nevertheless, the high cost of having a physi-
cian is a significant barrier for programs (Knudsen,
Abraham, and Oser 2011), as is the scarcity of addic-
tion medicine training in U.S. medical schools
(Polydorou, Gunderson, and Levin 2008). Future
research should consider examining whether programs
without physicians on staff or contracted for a portion
of their time make the decision not to employ physi-
cians due to funding reasons or due to an inconsis-
tency with their program’s treatment philosophy.
Table 4. Sources of treatment programs’ revenue (N = 200).
Wave 1 Wave 2
Wilcoxon’s signed-
rank tests
% of program
revenues from:
Medicaid 19.51 (25.98) 20.13 (26.10)
Medicare 1.41 (5.70) 2.13 (8.17)
Private insurance 12.12 (21.52) 12.52 20.63
Client fees 15.18 (22.92) 17.32 (25.90) *
Criminal justice 6.76 (16.49) 8.07 (19.16)
Federal block grants 14.48 (23.54) 11.53 (20.21) *
Other public grants 7.93 (16.89) 6.17 (14.51) *
*p < .05, **p < .01, ***p < .001.
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The ACA may facilitate use of pharmacotherapies
through co-existing parity legislation that requires that
SUD treatment services be covered by third-party
payers at the same level as services for other medical
problems (Buck 2011). Previous studies examined
adoption of individual medications, whereas the pre-
sent study considered several medications used for the
treatment of SUDs and co-occurring disorders.
More than half of the programs did not use any
medications and more than two-thirds did not use
SUD medications specifically. Overall, we found greater
usage of psychiatric medications compared to medica-
tions for SUD, and an increase in the availability of
antidepressants other than SSRIs. With the exception of
oral naltrexone and injectable naltrexone specifically
for opioid patients, we did not find a significant growth
in the availability of SUD medications over time. The
increase in the percentage of opioid patients receiving
injectable naltrexone was not surprising, given that
injectable naltrexone was only approved for opioid
use in late 2010.
A decrease in the implementation of acamprosate
and disulfiram could be due to patients substituting
other medications for these two, although we could
not measure this with our data. Disulfiram is the oldest
approved medication for SUD treatment, used primar-
ily for alcohol problems, but occasionally to treat
cocaine dependence. Based on mechanisms of operant
conditioning, it has long had mixed reviews among
SUD treatment personnel.
The use of MAT is a major move toward increased
medicalization, especially since it requires the presence
of medical personnel. One reason for the low levels of
implementation we observed is the lack of access to a
physician who can offer primary care services and pre-
scribe medications (Aletraris and Roman 2015;
Edmond et al. 2015; Knudsen, Roman, and Oser 2010;
Thomas et al. 2003). Even if an organization has
decided to use a medication, but only has a physician
on contract for a limited time, there may only be
enough physician time to evaluate, prescribe, and
monitor the medication among a few patients.
In terms of treatment philosophy, emphasis on the
12-step model was prevalent in both waves, and was
greater than the emphasis on the medical model. Some
programs regard pharmacotherapy as an adjunct to
treatment, rather than as a core treatment. However,
organizations that had adopted SUD medications were
more likely to place a greater emphasis on the medical
model compared to the 12-step model. While the 12-
step model is not completely incompatible with a med-
icalized approach to treatment, its emphasis on com-
plete abstinence from chemicals can be problematic
(Saxon and McCarty 2005). Over time, the data showed
a decrease in support for the 12-step model and an
increase on the emphasis of a medicalized treatment
model, indicative of a broader trend toward medica-
lized SUD treatment.
The ACA provides incentives to create co-locations
offering primary care and behavioral health services.
While there has been much attention on integrating
SUD services into medical care through either the crea-
tion of health homes or greater implementation of
SBIRT (Tai and Volkow 2013), this study considered
integration of medical services into SUD treatment
programs. We did not find a significant shift in the
provision of non-SUD health services, and availability
of these services was modest. For example, 13% of
programs provided primary care for their patients and
about a third provided HIV testing. Nonetheless, the
majority of programs did provide treatment for co-
occurring disorders, and there was a significant
increase in the number of programs that offered treat-
ment for such conditions. Since innovation adoption is
facilitated by the presence of similar and compatible
innovations (Rogers 2003), this finding is not surpris-
ing, given that treatment techniques for co-occurring
disorders are more closely aligned with standard SUD
treatment practices than interventions for other
diseases.
Finally, we found a small but significant shift away
from federal block grants and other public funding,
consistent with the expectations of the ACA. While
we did not find an increase in Medicaid or private
insurance revenues, research indicates that a significant
number of programs do not accept insurance (Terry-
McElrath, Chriqui, and McBride 2011). Programs that
have the ability to bill insurers and attract clients with
insurance will likely benefit from the number of new
enrollees afforded by the ACA.
Several limitations should be noted. The data were
self-reported and thus subject to recall bias, although
self-reporting is a common practice in organizational-
level research, including the N-SSATS. Data on adoption
and implementation of medications were self-reported by
clinical directors and were not validated by pharmacy
data. We did not ask for the specialties of FTE physicians,
so it is unclear whether physicians with an addiction
specialty were available in the programs. Future research
should examine factors that hinder the employment and
retention of different types of medical professionals in
SUD treatment programs. There also needs to be con-
sideration of differences in treatment outcomes asso-
ciated with having physicians on staff compared to
having a contractual relationship with them. These data
do not include state policy variables that could influence
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the medicalization of SUD treatment. We did not exam-
ine differences among programs in states that had
adopted Medicaid expansion and those that had declined
expansion. Examining the full impact of the ACA will
require longitudinal analyses that consider data from
insurance plans, state-level decisions, treatment organi-
zation, and patient characteristics.
Conclusion
In the context of the ACA, this study revealed an
increase in referrals from health care providers, num-
bers of physicians and other medical staff, and avail-
ability of a central medication, naltrexone, highlighting
a shift toward medicalized treatment. We also found a
shift away from federal block grants for SUD treatment
providers. These findings are consistent with the ACA,
indicating that it is having an impact. While many of
our revealed changes are small, most meet the standard
conditions of statistical significance. Additional studies
are needed to confirm this trajectory.
There is a long way to go before we see SUD treat-
ment integrated into mainstream medical care, and
patients being able to have confidence that the whole
range of their health care needs, including addiction,
are being met through accessible and quality medical
care. However, specialty SUD treatment has developed
over the past 50 years in almost complete isolation
from mainstream medicine. The SUD treatment pro-
grams in our sample are generally dominated by psy-
chosocial approaches, which, in turn, are reflected in
and by the professional credentials of their staff. Our
findings show low rates of adoption of MAT, primary
care services, and limited employment of medical pro-
fessionals. If these apparent barriers diminish over time
at the rates observed here, there may be cause to believe
that the integration goal of the ACA in regard to SUD
treatment will eventually be met.
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